Ionis Pharmaceuticals Inc (IONS) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) have received an average rating of “Hold” from the seventeen research firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $49.90.
IONS has been the subject of several analyst reports. Goldman Sachs Group restated a “sell” rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target for the company in a report on Friday, October 27th. Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Sunday, September 17th. Stifel Nicolaus restated a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Finally, BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th.
In other news, Chairman Stanley T. Crooke sold 22,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total value of $1,100,220.00. Following the completion of the sale, the chairman now owns 58,014 shares in the company, valued at approximately $2,901,280.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $58.35, for a total transaction of $58,350.00. Following the completion of the sale, the senior vice president now owns 11,433 shares of the company’s stock, valued at approximately $667,115.55. The disclosure for this sale can be found here. Insiders sold a total of 102,781 shares of company stock valued at $5,733,330 in the last quarter. 2.13% of the stock is currently owned by company insiders.
Ionis Pharmaceuticals (NASDAQ IONS) traded up $0.05 during trading on Monday, reaching $53.22. 946,500 shares of the company’s stock traded hands, compared to its average volume of 1,066,889. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals has a 52-week low of $37.26 and a 52-week high of $65.51. The company has a market cap of $6,620.00, a price-to-earnings ratio of 380.14 and a beta of 2.86.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.